
SION Stock Forecast & Price Target
SION Analyst Ratings
Bulls say
Sionna Therapeutics is viewed positively because its cystic fibrosis platform targets CFTR dysfunction through a differentiated NBD1 stabilizer strategy, which could address the disease’s underlying biology rather than only symptoms. The cited 14-day study showed that excluding outliers improved the observed sweat chloride change from -1.0 to -3.8 mmol/L, with the secondary analysis reaching -8.6 mmol/L, suggesting meaningful pharmacodynamic activity despite unusual non-adherence in a small trial. Management also believes the SION-451/SION-2222 regimen should avoid the drug-drug interaction concerns seen with SION-719 and Trikafta, strengthening confidence in the company’s lead combination approach.
Bears say
Sionna Therapeutics is viewed negatively because its Phase 2a PreciSION study failed to validate the company’s CFHBE platform, with SION-719 missing the primary sweat chloride endpoint at -1.0 mmol/L versus a >10 mmol/L goal and management discontinuing further development. The study’s interpretation was clouded by lower-than-expected Trikafta exposures, non-adherence concerns, and possible assay confounding, which raises fundamental doubts about whether its translational model can reliably predict meaningful clinical benefit in CF patients. With SION-451 still needing time to advance and safety/tolerability questions plus financing risk persisting, the stock appears range bound while the company relies on cash projected at about $4/share in 3Q26 and runway into 4Q28.
This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SION Analyst Forecast & Price Prediction
Start investing in SION
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sionna Therapeutics Inc (SION) Forecast
SION Analyst Forecast & Price Prediction
Start investing in SION
Order type
Buy in
Order amount
Est. shares
0 shares